Talphera (TLPH) Non-Current Deffered Revenue (2010 - 2022)
Talphera (TLPH) posted Non-Current Deffered Revenue of $1.0 million for Q4 2022, down 2.63% on a QoQ basis from $1.1 million in Q3 2022, and down 9.99% year-over-year from $1.2 million in Q4 2021.
Analysis
Talphera (TLPH) Non-Current Deffered Revenue (2010 - 2022) Analysis & Trends
Talphera has reported Non-Current Deffered Revenue for 13 years, with the latest figure at $1.0 million in Q4 2022.
- On a quarterly basis, Non-Current Deffered Revenue fell 9.99% year-over-year to $1.0 million in Q4 2022; TTM through Dec 2022 was $1.0 million, a 9.99% decrease from a year earlier, with the FY2022 full-year figure at $1.0 million, down 9.99% from the prior year.
- Non-Current Deffered Revenue was $1.0 million for Q4 2022 at Talphera, down from $1.1 million in the prior quarter.
- The five-year high for Non-Current Deffered Revenue was $3.4 million in Q1 2018, with the low at $1.0 million in Q4 2022.
- Average Non-Current Deffered Revenue over 5 years is $2.3 million, with a median of $2.8 million recorded in 2019.
- The sharpest annual moves came in 2018 and 2022: Non-Current Deffered Revenue retreated 9.1% in 2018, then dropped 13.99% in 2022.
- Over 5 years, Non-Current Deffered Revenue stood at $3.1 million in 2018, then retreated by 10.01% to $2.8 million in 2019, then retreated by 2.79% to $2.8 million in 2020, then plunged by 58.21% to $1.2 million in 2021, then retreated by 9.99% to $1.0 million in 2022.
- The last three Non-Current Deffered Revenue figures came in at $1.0 million (Q4 2022), $1.1 million (Q3 2022), and $1.1 million (Q2 2022), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 220.40 Mn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 147.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | - |
| 10 | Talphera | 92.90 Mn | 92.90 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2022 | 1.04 Mn |
| Sep 30, 2022 | 1.06 Mn |
| Jun 30, 2022 | 1.09 Mn |
| Mar 31, 2022 | 1.12 Mn |
| Dec 31, 2021 | 1.15 Mn |
| Sep 30, 2021 | 1.24 Mn |
| Mar 31, 2020 | 2.75 Mn |
| Dec 31, 2019 | 2.83 Mn |
| Sep 30, 2019 | 2.91 Mn |
| Jun 30, 2019 | 2.99 Mn |
| Mar 31, 2019 | 3.07 Mn |
| Dec 31, 2018 | 3.15 Mn |
| Sep 30, 2018 | 3.23 Mn |
| Jun 30, 2018 | 3.31 Mn |
| Mar 31, 2018 | 3.38 Mn |
| Dec 31, 2017 | 3.46 Mn |
| Sep 30, 2017 | 3.55 Mn |
| Jun 30, 2017 | 3.64 Mn |
| Mar 31, 2017 | 3.73 Mn |
| Dec 31, 2016 | 3.82 Mn |